Switching to riociguat: a potential treatment strategy for the management of CTEPH and PAH

Currently, five classes of drug are approved for the treatment of pulmonary arterial hypertension (PAH): phosphodiesterase 5 inhibitors (PDE5i); endothelin receptor antagonists; prostacyclin analogs; the IP receptor agonist selexipag; and the soluble guanylate cyclase (sGC) stimulator riociguat. For...

Descripción completa

Detalles Bibliográficos
Autores principales: Benza, Raymond L., Corris, Paul A., Ghofrani, Hossein-Ardeschir, Kanwar, Manreet, McLaughlin, Vallerie V., Raina, Amresh, Simonneau, Gérald
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7074518/
https://www.ncbi.nlm.nih.gov/pubmed/30803329
http://dx.doi.org/10.1177/2045894019837849

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7074518/
https://www.ncbi.nlm.nih.gov/pubmed/30803329
http://dx.doi.org/10.1177/2045894019837849

Ejemplares similares